A physiologically based pharmacokinetic model combines information about a drug with assumptions about physiology. Researchers used this approach to estimate how isavuconazole might interact with other drugs in children when direct interaction data were limited.
The team built and checked the isavuconazole model against adult and pediatric pharmacokinetic data. It then simulated interaction scenarios based on adult studies, using pediatric doses. The simulations generally predicted similar interaction effects across ages, with a tendency toward larger exposure ratios in the youngest group under one dosing scenario.
The pediatric interaction ratios are outputs of the model. They do not represent directly measured interactions in all the child populations and drug combinations simulated. Interpreting a number requires its age range, dose, comparator, and supporting validation data. The paper identifies areas where clinical verification remains limited.
Choules et al., Journal of Pharmacokinetics and Pharmacodynamics ยท Full text